ABDOMINAL AORTIC ANEURYSM REPAIR DEVICES MARKET ANALYSIS

Market Challenges And Opportunities

Abdominal Aortic Aneurysm Repair Devices Market Drivers

Key players in the abdominal aortic aneurysm repair devices market have launched various new products for AAA treatment and this has positively affected growth of the market. For instance, in 2017, Lombard Medical Inc. received approval from the Japanese Ministry of Health, Labour and Welfare for its new IntelliFlex Low Profile (LP) Delivery System for the Aorfix Endovascular Stent Graft. In 2016, Lombard Medical, Inc. received CE Mark approval for its IntelliFlex Low Profile (LP) Delivery System for the Aorfix Endovascular Stent Graft. In 2013, Lombard Medical Inc. launched its Aorfix, a latest endovascular stent graft in the U.S. market. In 2014, Cordis Corporation (now a part of Cardinal Health, Inc.) launched its INCRAFT AAA Stent Graft System (INCRAFT System), a device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal AAA. In 2015, Endologix, Inc. received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its AFX Endovascular AAA System for the treatment of abdominal aortic aneurysms. In 2014, Medtronic Plc. received approval for its new Endurant IIs in the U.S. and Europe. Endurant IIs is a latest stent graft system for the endovascular repair of abdominal aortic aneurysms. These approvals have led to development of novel products in the market, which is expected to drive growth of global abdominal aortic aneurysm repair devices market in the near future. Increasing collaborations and acquisition activities by key players in market is also expected to support growth of global abdominal aortic aneurysm repair devices. For instance, in 2016, Microport Scientific Corp.—a China-based company—entered in strategic partnership with Lombard Medical Inc. According to the partnership, Microport Scientific Corp. invested US$ 15 million in Lombard Medical Inc. and gained exclusive marketing rights of Lombard’s Aorfix and Altura stent graft in China and Brazil as well as the manufacturing rights in China. In 2015, Cardinal Health Inc. completed the acquisition of Johnson & Johnson's Cordis business at US$ 1.9 billion.